SIREN : 420965758
EURAXI PHARMA is a French company founded 27 years ago, specialized in the sector Analyses, essais et inspections techniques. Based in JOUE-LES-TOURS (37300), this company of category PME shows in 2022 a revenue of 13.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | N/C | N/C | 13 269 867 € | 7 953 945 € | 4 782 216 € | 4 852 260 € | 4 311 728 € |
| Net income | -397 990 € | 320 184 € | 2 425 887 € | 1 665 409 € | 376 049 € | 344 096 € | 8 647 € |
| EBITDA | N/C | N/C | 3 129 677 € | 1 713 600 € | 267 671 € | 317 781 € | -20 185 € |
| Net margin | N/C | N/C | 18.3% | 20.9% | 7.9% | 7.1% | 0.2% |
In 2024, EURAXI PHARMA records a net loss of 398 k€. This deficit will reduce equity on the balance sheet.
-397 990 €
The debt ratio (= Financial debt / Equity x 100) stands at 10%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 53%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
9.986%
53.394%
38.3%
In 2024, the debt ratio of EURAXI PHARMA (9.99) ranks below the median of the sector. This ratio measures the weight of debt relative to equity. This controlled position reflects prudent management.
In 2024, the financial autonomy of EURAXI PHARMA (53.4%) ranks above the median of the sector. This ratio represents the share of equity in total financing. This comfortable position offers an appreciable safety margin.
In 2022, the repayment capacity of EURAXI PHARMA (0.14) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 158.92. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
158.919
In 2024, the liquidity ratio of EURAXI PHARMA (158.92) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2022, the interest coverage of EURAXI PHARMA (0.1x) ranks above the median of the sector. This ratio indicates how many times operating income covers interest expenses. This comfortable position offers an appreciable safety margin.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
0 €
0 j
0 j
0 j
Compare EURAXI PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Analyses, essais et inspections techniques
The revenue of EURAXI PHARMA in 2022 is 13.3 M€.
EURAXI PHARMA recorded a net loss in 2024.
The headquarters of EURAXI PHARMA is located in JOUE-LES-TOURS (37300), in the department Indre-et-Loire.
The tax return of EURAXI PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
EURAXI PHARMA operates in the sector Analyses, essais et inspections techniques (NAF code 71.20B). See the 'Sector positioning' section above to compare the company with its competitors.